RxDoctor Payments Data

Patrick Evivie, MD

Internal Medicine · Charlotte, NCNPI 1285612374

Payments from drug & device makers

$12,623in general payments, 2019–2025

Across 736 payments — averaging $17.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Novo Nordisk$2K
  • Lilly USA, LLC$1K
  • Boehringer Ingelheim$853
  • Amgen$840
  • Pfizer$800
  • plus $5K from 36 others

What the payments were for

  • Food & beverage$12,593100%
  • Education$300%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,623 in reported general payments places this provider in the 90th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$114,971
Medicare patients
183
Services billed
2,100

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide77$109,202
JardianceEmpagliflozin62$79,552
Trelegy ElliptaFluticasone/Umeclidin/Vilanter95$62,939
FarxigaDapagliflozin Propanediol29$38,755
MounjaroTirzepatide25$38,407
XareltoRivaroxaban22$28,148
EliquisApixaban27$26,461
JanuviaSitagliptin Phosphate13$15,408
TrulicityDulaglutide13$15,250
SymbicortBudesonide/Formoterol Fumarate33$12,091
Lantus SolostarInsulin Glargine,hum.Rec.Anlog74$11,860
Spiriva HandihalerTiotropium Bromide13$10,819
LinzessLinaclotide13$9,485
InvokanaCanagliflozin14$9,431
MitigareColchicine25$6,323

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,524$109,20277 claims
Boehringer IngelheimJardiance$853$79,55262 claims
GSKTrelegy Ellipta$403$62,93995 claims
Lilly USA, LLCMounjaro, Trulicity$1,082$53,65638 claims
AstraZenecaFarxiga, Symbicort$2,265$50,84562 claims
Johnson & JohnsonXarelto, Invokana$546$37,58036 claims
PfizerEliquis$800$26,46127 claims
MerckJanuvia$225$15,40813 claims
AbbVieLinzess$518$9,48513 claims
Hikma Pharmaceuticals USAMitigare$156$6,32325 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →